<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-AIP5SSU6/7b10b027-31af-4421-96a3-f70c48568ffe/PDF"><dcterms:extent>552 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-AIP5SSU6/10ae49e3-b37f-47eb-b3c6-df69d9f7b2b2/TEXT"><dcterms:extent>41 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-AIP5SSU6"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2022</dcterms:issued><dc:creator>Cvikl Knehtl, Maja</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:73</dc:format><dc:format xml:lang="sl">str. 54-63</dc:format><dc:identifier>COBISSID_HOST:140694019</dc:identifier><dc:identifier>ISSN:2536-4316</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-AIP5SSU6</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="en">antibiotics</dc:subject><dc:subject xml:lang="sl">Antibiotiki</dc:subject><dc:subject xml:lang="en">antimicrobial drugs</dc:subject><dc:subject xml:lang="en">critically ill patients</dc:subject><dc:subject xml:lang="sl">dializne metode</dc:subject><dc:subject xml:lang="en">dialysis techniques</dc:subject><dc:subject xml:lang="sl">farmakokinetično/farmakodinamični indeks</dc:subject><dc:subject xml:lang="sl">kritično bolni</dc:subject><dc:subject xml:lang="sl">ledvična funkcija</dc:subject><dc:subject xml:lang="en">pharmacokinetic/pharmacodynamic index</dc:subject><dc:subject xml:lang="sl">protimikrobna zdravila</dc:subject><dc:subject xml:lang="en">renal clearance</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Prilagajanje odmerjanja protimikrobnih zdravil pri kritično bolnih| Dose adjustments of antimicrobial drugs in critically ill patients|</dc:title><dc:description xml:lang="sl">Dosing of antimicrobial drugs in critically ill patients remains challenging. Choosing an appropriate antimicrobial drug with effectiveness against the most likely pathogen, as well as the selection of an appropriate dosing regimen that will provide therapeutic concentration at the site of infection, is essential. When choosing a dosing regimen we should consider the phamacokinetic properties of the selected antimicrobial agents (hydrophilicity and lipophilicity, pharmacokinetic/pharmacodinamic index), the patient’s individual parameters (body weight, effect of critically illness on pharmacokinetics, kidney function – acute kidney failure, augmented renal clearance or possible application of different dialysis techniques, and extracorporeal membrane oxygenation) and susceptibility of the causative pathogen. This review article summarises factors to be considered in adjusting the dosing regimen of antimicrobial drugs in critically ill patients</dc:description><dc:description xml:lang="sl">Odmerjanje protimikrobnih zdravil pri bolnikih v intenzivni enoti predstavlja velik izziv. Izbrati je treba protimikrobno zdravilo, ki bo učinkovito proti najverjetnejšemu povzročitelju, pomembna pa je tudi izbira ustreznega odmerjanja, ki bo zagotavljalo terapevtske koncentracije na mestu okužbe. Pri izbiri odmerka je treba upoštevati lastnosti protimikrobne učinkovine (hidrofilnost ali lipofilnost, farmakokinetično/farmakodinamični indeks učinkovitosti), posebnosti bolnika (telesna masa, vpliv kritične bolezni na farmakokinetiko, ledvično delovanje – akutna ledvična odpoved, pospešena ledvična funkcija, morebitna priključitev na dializno napravo in/ali zunajtelesni krvni obtok) ter občutljivost mikroorganizma. Pregledni članek podrobneje povzema dejavnike, ki jih je treba upoštevati pri prilagajanju odmerjanja protimikrobnih zdravil pri bolnikih na intenzivni enoti</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-AIP5SSU6"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-AIP5SSU6" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-AIP5SSU6/7b10b027-31af-4421-96a3-f70c48568ffe/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-AIP5SSU6/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-AIP5SSU6" /></ore:Aggregation></rdf:RDF>